Editorial: can experimental biomarkers be useful for predicting HCC occurrence after sustained viral response in clinical settings?

Affiliations

Editorial

Tetsuya Hosaka. Aliment Pharmacol Ther. 2022 Jan.

. 2022 Jan;55(1):137-138.

doi: 10.1111/apt.16716.

No abstract available

Comment on

Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Aliment Pharmacol Ther. 2022 Feb;55(4):422-433. doi: 10.1111/apt.16691. Epub 2021 Nov 23. Aliment Pharmacol Ther. 2022. PMID: 34812502 Clinical Trial.

1. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71:44-55.
1. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68:526-549.
1. Moyjin Y, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther. 2021. https://doi.org/10.1111/apt.16691.
1. Myojin Y, Hikita H, Sugiyama M, et al. Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production. Gastroenterology. 2021;160:1741-1754.
1. Tsai VWW, Husaini Y, Sainsbury A, Brown DA, Breit SN. The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28:353-368.